Nonrecourse Debt, at Fair Value |
|
Nonrecourse Debt, at Fair Value | Nonrecourse debt, at fair value, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securitization of nonperforming HECM loans: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
February 2021 |
|
A, M1, M2, M3, M4, M5 |
|
February 2031 |
|
|
0.9%—9.0% |
|
|
$ |
571,448 |
|
|
|
|
|
|
|
|
$ |
— |
|
|
|
July 2020 |
|
A, M1, M2, M3, M4, M5 |
|
July 2030 |
|
|
1.71%—7.75% |
|
|
|
594,171 |
|
|
|
|
|
|
|
|
|
476,147 |
|
|
|
February 2020 |
|
A, M1, M2, M3, M4, M5 |
|
February 2030 |
|
|
2.0%—6.0% |
|
|
|
373,912 |
|
|
|
|
|
|
|
|
|
298,883 |
|
|
|
|
|
|
|
Securitization of non-agency reverse loans: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
April 2021 |
|
A1, A2 |
|
April 2026 |
|
|
1.5%—2.0% |
|
|
|
562,512 |
|
|
|
|
|
|
|
|
|
— |
|
|
|
June 2019 |
|
A, A2 |
|
June 2069 |
|
|
2.0% |
|
|
|
499,000 |
|
|
|
|
|
|
|
|
|
440,141 |
|
|
|
May 2018 |
|
A |
|
May 2068 |
|
|
4.3% |
|
|
|
559,197 |
|
|
|
|
|
|
|
|
|
428,671 |
|
|
|
September 2019 |
|
A |
|
September 2069 |
|
|
2.0% |
|
|
|
450,104 |
|
|
|
|
|
|
|
|
|
404,057 |
|
|
|
August 2020 |
|
A, A2 |
|
August 2025 |
|
|
2.0%—3.0% |
|
|
|
360,713 |
|
|
|
|
|
|
|
|
|
337,099 |
|
|
|
November 2019 |
|
A |
|
November 2069 |
|
|
2.0% |
|
|
|
365,685 |
|
|
|
|
|
|
|
|
|
335,945 |
|
|
|
March 2019 |
|
A |
|
March 2069 |
|
|
2.0% |
|
|
|
347,000 |
|
|
|
|
|
|
|
|
|
309,840 |
|
|
|
December 2020 |
|
A1, A2 |
|
December 2025 |
|
|
1.5%—2.5% |
|
|
|
313,357 |
|
|
|
|
|
|
|
|
|
297,871 |
|
|
|
June 2020 |
|
A1, A2 |
|
March 2025 |
|
|
2.0% |
|
|
|
320,460 |
|
|
|
|
|
|
|
|
|
299,401 |
|
|
|
May 2020 |
|
A1A, A1B, A2 |
|
May 2023 |
|
|
0.0%—2.0% |
|
|
|
305,658 |
|
|
|
|
|
|
|
|
|
291,827 |
|
|
|
December 2018 |
|
A |
|
December 2068 |
|
|
4.5% |
|
|
|
280,400 |
|
|
|
|
|
|
|
|
|
253,325 |
|
|
|
October 2020 |
|
A, A2 |
|
August 2025 |
|
|
2.0%—3.0% |
|
|
|
241,664 |
|
|
|
|
|
|
|
|
|
217,385 |
|
|
|
March 2020 |
|
A1, A2 |
|
March 2025 |
|
|
2.0%—3.7% |
|
|
|
199,000 |
|
|
|
|
|
|
|
|
|
181,059 |
|
|
|
April 2020 |
|
A, A2 |
|
April 2023 |
|
|
2.0% |
|
|
|
254,805 |
|
|
|
|
|
|
|
|
|
240,563 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securitization of Fix & Flip loans: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
April 2021 |
|
A1, A2, M |
|
November 2024 (A1); January 2025 (A2); May 2025 (M) |
|
|
2.1%—5.4% |
|
|
|
268,511 |
|
|
|
|
|
|
|
|
|
— |
|
|
|
May 2020 |
|
A1, A2 |
|
May 2022 (A1, A2) |
|
|
6.9%—8.0% |
|
|
|
306,517 |
|
|
|
|
|
|
|
|
|
140,072 |
|
|
|
September 2018 |
|
|
|
July 2022 (A1, A2); March 2023 (M) |
|
|
4.3%—7.4% |
|
|
|
210,296 |
|
|
|
|
|
|
|
|
|
80,949 |
|
|
|
March 2019 |
|
A1, A2, A-VFN, M |
|
June 2022 (A1, A2); January 2023 (M) |
|
|
4.5%—6.9% |
|
|
|
217,100 |
|
|
|
|
|
|
|
|
|
121,772 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,155,007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonrecourse MSR financing liability, at fair value |
|
|
|
|
|
|
|
|
|
14,088 |
|
|
|
|
|
|
|
|
|
|
|
102,747 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total nonrecourse debt, at fair value |
|
|
|
|
|
|
|
|
$ |
5,271,842 |
|
|
|
|
|
|
|
|
|
|
|
|
| Nonrecourse MSR Financing Liability, at Fair Value The Company has agreements with third parties to sell beneficial interests in the servicing fees generated from certain of its originated or acquired mortgage servicing rights. Under these agreements, the Company has agreed to sell to the third parties the right to receive all excess servicing and ancillary fees related to the identified MSRs in exchange for an upfront payment equal to the entire purchase price of the identified mortgage servicing rights. These transactions are accounted for as financings under ASC 470 and included in nonrecourse debt, at fair value in the Consolidated Statements of Financial Condition. The Company elected to measure the outstanding financings related to the nonrecourse MSR financing liability, at fair value, as permitted under ASC 825 , with all changes in fair value recorded as a charge or credit to fee income in the Consolidated Statements of Operations. The fair value on the nonrecourse MSR financing liability is based on the present value of expected future cash flows to be paid to the third parties with the discount rate approximating current market value for similar financial instruments. See Note 30—Related Party Transactions for additional information regarding the nonrecourse MSR financing liability.
|